Loading...
NPI 1306068135 · Chattanooga, TN · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Robert Graham is a hematology & oncology physician provider located in Chattanooga, Tennessee. This profile covers 76 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Robert Graham |
| Address | 1032 Mccallie Ave Ste 200 |
| City | Chattanooga |
| State | TN |
| ZIP | 37403 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | May 2, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.2M |
| Medicaid | $19.8K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
76 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 11,800 | $40 | $519.2K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 100 | $1,030 | $104.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 790 | $120 | $97.6K |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 80 | $840 | $66.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 510 | $90 | $45K |
| J0897 | Injection, denosumab, 1 mg | 2,040 | $20 | $30.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 360 | $80 | $30.6K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 320 | $80 | $26.2K |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 70 | $340 | $24.8K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 20,250 | $1 | $20.3K |
Showing 1–10 of 76
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 76 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
76 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 38 | 50 | 17,400 | $40 | $776.1K |
| A9596 | 8 | 10 | 130 | $820 | $118.5K |
| J0897 | 153 | 240 | 2,940 | $20 | $85K |
| J2506 | 34 | 40 | 430 | $80 | $46.7K |
| J1439 | 69 | 90 | 34,130 | $1 | $38.6K |
| 78815 | 53 | 150 | 70 | $350 | $38.5K |
| J1454 | 32 | 70 | 70 | $340 | $25.6K |
| J9217 | 83 | 110 | 130 | $130 | $22K |
| 96413 | 25 | 240 | 150 | $90 | $18.9K |
| A9552 | 13 | 40 | 60 | $200 | $18.6K |
Showing 1–10 of 76
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 260 | $50 | $12.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 190 | $30 | $4.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 320 | $10 | $2.2K |
How this provider's Medicaid billing volume and revenue compare to other Tennessee providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Tennessee median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 2,395 | 3,760 | 610 | $40 | $202.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,747 | 4,050 | 620 | $30 | $183.9K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 391 | 550 | 1,210 | $1 | $50.1K |
Other providers in the same ZIP code as Robert Graham, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.